Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dalpiciclib + Letrozole with Trastuzumab Deruxtecan (SHR-A1811) Switch in HR+/HER2-low Breast Cancer
ChiCTR2500110276Phase 4Not yet recruiting
- Sponsor
- Anyang Cancer Hospital
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab deruxtecan, dalpiciclib and letrozole in breast cancer, sponsored by Anyang Cancer Hospital. Primary endpoint: Objective response rate (ORR). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecandalpiciclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500110276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110276.